Vericel reports Q2 earnings beat, raises outlook
Vericel Corporation (NASDAQ: VCEL) reported better-than-expected results in the second quarter aided by strong growth from both of its products....
Vericel Corporation (NASDAQ: VCEL) reported better-than-expected results in the second quarter aided by strong growth from both of its products....
Clovis Oncology (NASDAQ: CLVS) on Thursday reported second-quarter results that were weaker than the street expectations. Total revenues rose 39%...
Swiss pharmaceutical giant Novartis (NYSE: NVS) on Thursday surprised Wall Street by reporting a year-over-year increase in net earnings in...
Novartis AG (NYSE: NVS) is scheduled to report second-quarter earnings before the opening bell on Thursday, July 18. The Switzerland-based...
AngioDynamics (NASDAQ: ANGO) posted fourth-quarter earnings results on Wednesday before the regular trading hours. Net sales for the period increased 9%...
Canadian producer of wellness products, Neptune Wellness Solutions (NASDAQ: NEPT), said its revenues fell 16% in the first quarter to...
Late-stage biotech firm Advaxis, Inc. (NASDAQ: ADXS) is scheduled to report second-quarter financial results on June 10, Monday, after the...
Shares of Solid Biosciences Inc. (NASDAQ: SLDB) opened 38% lower on Tuesday after the company said in its first-quarter results...
Israel-based medical device company InspireMD (NYSE: NSPR) reported a first-quarter loss of $3.82 per share, much wider than the loss...
Intercept Pharmaceuticals (NASDAQ: ICPT) reported wider-than-expected losses in the first quarter of 2019, primarily due to higher R&D expenses related...
Array BioPharma (NASDAQ: ARRY) reported a narrower-than-expected loss in the third quarter of 2019, sending its shares up 0.5% during...
Medical marijuana company GW Pharmaceuticals (NASDAQ: GWPH) is scheduled to report first-quarter 2019 earnings results on May 6, Monday, after...
ImmunoGen Inc (NASDAQ: IMGN) on Friday reported weaker-than-expected top line in Q1, as the biotech firm continued to burn money...
Shares of Gilead Sciences (NASDAQ: GILD) gained 1.2% after the biotechnology firm reported first-quarter earnings of $1.76 per share, surpassing...
ImmunoGen Inc (NASDAQ: IMGN) is one of the worst performing stocks out there, losing about 78% of its value over...
Gilead Sciences (NASDAQ: GILD) has tested its investors enough lately. The stock has increased just 2.5% in the year-to-date period,...
Amarin Corporation (NASDAQ: AMRN) on Wednesday said its revenues soared 67% to $73.3 million, riding on the strong demand for...
Shares of the pharma giant Merck (MRK) rose 2% before the market hours after the company surpassed estimates on the...
Amarin Corporation (NASDAQ: AMRN)Β is scheduled to report first-quarter 2019 earnings results on Wednesday, May 1, before the opening bell. Analysts...
Riding on the strong demand for its cancer drugs, AstraZeneca Plc (NYSE: AZN) on Friday reported its third consecutive quarter...
Biopharma company Bristol-Myers Squibb (NYSE: BMY) on Thursday reported better-than-expected first-quarter 2019 results, sending its shares up over 1% during...